201. Evaluation of the Safety of Fibrinogen Concentrate Administration for Bleeding Control in Neurosurgery
- Author
-
Helder Tedeschi, Cristiane Tavares, Seigi Sazaki, Kazuco Nakai Murata, and Andrei F. Joaquim
- Subjects
medicine.medical_specialty ,business.industry ,Fibrinogen ,Neurosurgical Procedure ,Bleeding control ,Anesthesia ,Medicine ,In patient ,Platelet ,Neurosurgery ,business ,Adverse effect ,Prospective cohort study ,medicine.drug - Abstract
Background and Objective: Bleeding control is extremely important in any surgical procedure, especially in neurological surgery. Hemodilution with colloid and crystalloid may predispose to functional impairment of fibrinogen, which replacement may be beneficial. We evaluated the safety of fibrinogen concentrate administration in patients who underwent a neurosurgical procedure. Method: We reviewed the medical charts of a series of consecutive patients who received prophylactic fibrinogen concentrate and underwent a neurosurgical procedure for different pathologies in our institution from July 2009 to July 2010. Adverse effects, red blood cells and platelet transfusions were carefully recorded in all cases. Results: Twelve patients were included in our study. There were seven (58%) men and five (42%) women, with a median age of 37 years. All patients had a normal baseline laboratory tests. There was no case of allergic reactions or any adverse events related to fibrinogen administration. None of them required red blood cells or platelet transfusions after surgery, and there were no thrombotic events during 30 days of follow-up. Conclusion: The prophylactic use of fibrinogen concentrate appears to be safe in neurosurgery and may reduce the need of blood derivatives transfusion. Additional prospective studies should be performed to assess the efficacy of this strategy.
- Published
- 2018
- Full Text
- View/download PDF